GRIONI, Andrea, G. FAZIO, S. RIGAMONTI, Vojtěch BYSTRÝ, G. DANIELE, Zuzana DOSTÁLOVÁ, M. QUADRI, C. SAITTA, D. SILVESTRI, S. SONGIA, C.T. STORLAZZI, A. BIONDI, Nikos DARZENTAS and G. CAZZANIGA. A Simple RNA Target Capture NGS Strategy for Fusion Genes Assessment in the Diagnostics of Pediatric B-cell Acute Lymphoblastic Leukemia. HEMASPHERE. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2019, vol. 3, No 3, p. 1-9. ISSN 2572-9241. Available from: https://dx.doi.org/10.1097/HS9.0000000000000250.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name A Simple RNA Target Capture NGS Strategy for Fusion Genes Assessment in the Diagnostics of Pediatric B-cell Acute Lymphoblastic Leukemia
Authors GRIONI, Andrea (380 Italy, belonging to the institution), G. FAZIO, S. RIGAMONTI, Vojtěch BYSTRÝ (203 Czech Republic, belonging to the institution), G. DANIELE, Zuzana DOSTÁLOVÁ (203 Czech Republic, belonging to the institution), M. QUADRI, C. SAITTA, D. SILVESTRI, S. SONGIA, C.T. STORLAZZI, A. BIONDI, Nikos DARZENTAS (300 Greece, belonging to the institution) and G. CAZZANIGA.
Edition HEMASPHERE, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2019, 2572-9241.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14740/19:00113287
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1097/HS9.0000000000000250
UT WoS 000501818000011
Keywords in English HIGH-RISK; EXPRESSION; IKZF1; CRLF2
Tags CF BIOIT, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 17/3/2020 18:27.
Abstract
Acute lymphoblastic leukemia (ALL) is the most frequent pediatric cancer. Fusion genes are hallmarks of ALL, and they are used as biomarkers for risk stratification as well as targets for precision medicine. Hence, clinical diagnostics pursues broad and comprehensive strategies for accurate discovery of fusion genes. Currently, the gold standard methodologies for fusion gene detection are fluorescence in situ hybridization and polymerase chain reaction; these, however, lack sensitivity for the identification of new fusion genes and breakpoints. In this study, we implemented a simple operating procedure (OP) for detecting fusion genes. The OP employs RNA CaptureSeq, a versatile and effortless next-generation sequencing assay, and an in-house as well as a purpose-built bioinformatics pipeline for the subsequent data analysis. The OP was evaluated on a cohort of 89 B-cell precursor ALL (BCP-ALL) pediatric samples annotated as negative for fusion genes by the standard techniques. The OP confirmed 51 samples as negative for fusion genes, and, more importantly, it identified known (KMT2A rearrangements) as well as new fusion events (JAK2 rearrangements) in the remaining 38 investigated samples, of which 16 fusion genes had prognostic significance. Herein, we describe the OP and its deployment into routine ALL diagnostics, which will allow substantial improvements in both patient risk stratification and precision medicine.
PrintDisplayed: 20/7/2024 09:35